Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer

- Proceeds will support development of lead clinical programs, RBN-2397 and RBN-3143, while advancing early-stage pipeline derived from Ribon’s BEACON⁺ platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical-stage biotechnology company developing therapeutics to target stress support pathways, today announced a $25 million investment from Pfizer. Ribon plans to use the proceeds to support clinical development of its potentially first-in-class oral small molecule programs in oncology (RBN-2397, a PARP7 inhibitor) and immunology (RBN-3143, a PARP14 inhibitor). As part of the investment, Robert Rickert, Ph.D., Senior Vice President and Head of Cancer Immunology Discovery, Pfizer, will join Ribon’s Scientific Advisory Board.

Separately, Ribon and Pfizer have entered into an agreement to leverage Pfizer’s global development expertise and capabilities to support the advancement of Ribon’s pipeline. Ribon will retain economic rights and control of clinical development across all its programs.

“We thank Pfizer for its investment in Ribon and support of our novel approach to developing potential first-in-class treatments targeting stress support pathways, and we welcome Dr. Rickert to our Scientific Advisory Board,” said Prakash Raman, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “Pfizer’s capital support and expertise will be instrumental as we work to advance our lead programs—RBN-2397 in cancer and RBN-3143 in immunology—to key clinical milestones and enable further drug discovery and development from our proprietary BEACON⁺ platform.”

“We believe Ribon’s pioneering work to develop therapeutics that target stress support pathways represents a potential breakthrough for patients living with cancer and inflammatory diseases,” said Dr. Rickert. “I look forward to working with the Ribon team to help advance their important clinical programs.”

About Ribon Therapeutics
Ribon Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. Ribon’s portfolio includes two oral, potentially first-in-class clinical programs, RBN-2397 (a PARP7 inhibitor) and RBN-3143 (a PARP14 inhibitor), with potential broad indications in oncology and inflammatory diseases, respectively. The company explores novel areas of biology with the goal of developing effective treatments for patients with limited therapeutic options.

Leveraging its proprietary BEACON⁺ (Blocking the Enzyme Activity Component of NAD⁺) platform, Ribon is building a pipeline of selective, small molecule inhibitors to numerous NAD⁺-utilizing enzymes, beginning with monoARTs (mono-ADP-ribosyltransferase), which have applications across multiple therapeutic areas. Ribon is located in Cambridge, Massachusetts. For more information, visit https://ribontx.com/.